Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5aantibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc^[1].

Vilobelimab selectively neutralises C5a in a dose-dependent manner without blocking the formation of the membrane attack complex and without leading to detectable safety concerns In certain clinical studies of patients suffering from severe sepsis and septic shock^[1].

2250440-41-4

Please store the product under the recommended conditions in the Certificate of Analysis.